Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
| 0.216 | |
| 0.216 | |
| - | |
| 0.216 | |
| 0.216 | |
| 0.111-0.886 | |
| 11 429 K | |
| 53 009 K | |
| 9 713 K | |
| 0.169 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
We feel now is a pretty good time to analyse Antibe Therapeutics Inc.'s (TSE:ATE) business as it appears the company may be on the cusp of a considerable accomplishment. Antibe Therapeutics Inc., a bi...
- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $3...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
